Comprehensive Stock Comparison
Compare Fortress Biotech, Inc. (FBIO) vs Nurix Therapeutics, Inc. (NRIX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | NRIX | 54.0% revenue growth vs FBIO's -31.8% |
| Quality / Margins | FBIO | 6.4% net margin vs NRIX's -314.9% |
| Stability / Safety | FBIO | Beta 0.65 vs NRIX's 1.19 |
| Dividends | FBIO | 1.0% yield; NRIX pays no meaningful dividend |
| Momentum (1Y) | FBIO | +117.8% vs NRIX's +3.4% |
| Efficiency (ROA) | FBIO | 2.2% ROA vs NRIX's -38.4%, ROIC -6.3% vs -54.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Fortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products across multiple therapeutic areas. It generates revenue primarily through sales of its marketed dermatology products — including treatments for acne and skin conditions — supplemented by milestone payments and potential future royalties from its extensive pipeline of late-stage and early-stage drug candidates. The company's key advantage lies in its diversified portfolio approach, which spreads risk across multiple development programs while leveraging partnerships to fund research and development.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and immune disorders. It generates revenue primarily through strategic collaborations and licensing deals — including partnerships with Gilead Sciences and Sanofi — while advancing its own pipeline of oral BTK degraders and CBL-B inhibitors. The company's key advantage is its proprietary DELigase platform for discovering novel protein degraders, which could enable treatments for diseases that have been difficult to target with conventional small molecules.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FBIO leads in 2 of 6 categories (Financial Metrics, Risk & Volatility). NRIX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
NRIX and FBIO operate at a comparable scale, with $84M and $62M in trailing revenue. FBIO is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to NRIX's -3.1%. On growth, FBIO holds the edge at +20.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $62M | $84M |
| EBITDAEarnings before interest/tax | -$88M | -$267M |
| Net IncomeAfter-tax profit | $4M | -$264M |
| Free Cash FlowCash after capex | -$66M | -$263M |
| Gross MarginGross profit ÷ Revenue | +65.8% | -87.4% |
| Operating MarginEBIT ÷ Revenue | -149.2% | -3.4% |
| Net MarginNet income ÷ Revenue | +6.4% | -3.1% |
| FCF MarginFCF ÷ Revenue | -106.2% | -3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.5% | +2.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +114.5% | -9.3% |
Valuation Metrics
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| Market CapShares × price | $95M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $114M | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.27x | -5.24x |
| Forward P/EPrice ÷ next-FY EPS est. | 342.00x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 19.36x |
| Price / BookPrice ÷ Book value/share | — | 2.57x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FBIO delivers a 6.1% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-49 for NRIX. On the Piotroski fundamental quality scale (0–9), NRIX scores 4/9 vs FBIO's 1/9, reflecting mixed financial health.
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | +6.1% | -49.1% |
| ROA (TTM)Return on assets | +2.2% | -38.4% |
| ROICReturn on invested capital | -6.3% | -54.0% |
| ROCEReturn on capital employed | -142.0% | -48.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.10x |
| Net DebtTotal debt minus cash | $19M | -$191M |
| Cash & Equiv.Liquid assets | $57M | $247M |
| Total DebtShort + long-term debt | $76M | $56M |
| Interest CoverageEBIT ÷ Interest expense | -4.25x | — |
Total Returns (with DRIP)
A $10,000 investment in NRIX five years ago would be worth $4,406 today (with dividends reinvested), compared to $588 for FBIO. Over the past 12 months, FBIO leads with a +117.8% total return vs NRIX's +3.4%. The 3-year compound annual growth rate (CAGR) favors NRIX at 19.2% vs FBIO's -33.3% — a key indicator of consistent wealth creation.
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -15.1% | -11.6% |
| 1-Year ReturnPast 12 months | +117.8% | +3.4% |
| 3-Year ReturnCumulative with dividends | -70.4% | +69.4% |
| 5-Year ReturnCumulative with dividends | -94.1% | -55.9% |
| 10-Year ReturnCumulative with dividends | -92.0% | -16.0% |
| CAGR (3Y)Annualised 3-year return | -33.3% | +19.2% |
Risk & Volatility
FBIO is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than NRIX's 1.19 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FBIO currently trades 75.5% from its 52-week high vs NRIX's 71.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 1.19x |
| 52-Week HighHighest price in past year | $4.53 | $22.50 |
| 52-Week LowLowest price in past year | $1.33 | $8.18 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +71.0% |
| RSI (14)Momentum oscillator 0–100 | 51.9 | 45.3 |
| Avg Volume (50D)Average daily shares traded | 729K | 946K |
Analyst Outlook
Wall Street rates FBIO as "Buy" and NRIX as "Buy". FBIO is the only dividend payer here at 0.98% yield — a key consideration for income-focused portfolios.
| Metric | FBIOFortress Biotech,… | NRIXNurix Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $31.22 |
| # AnalystsCovering analysts | 6 | 17 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | 100 | 7.24 | -92.8% |
| Nurix Therapeutics,… (NRIX) | 100.58 | 89.9 | -10.6% |
Nurix Therapeutics,… (NRIX) returned -56% over 5 years vs Fortress Biotech, I… (FBIO)'s -94%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | $16M | $58M | +250.0% |
| Nurix Therapeutics,… (NRIX) | $37M | $84M | +124.3% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -3.3% | -79.8% | -2285.5% |
| Nurix Therapeutics,… (NRIX) | -25.2% | -3.1% | +87.5% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -20.68 | -2.69 | +87.0% |
| Nurix Therapeutics,… (NRIX) | -0.59 | -3.05 | -416.9% |
Chart 5Free Cash Flow — 5 Years
Fortress Biotech, Inc. generated $-95M FCF in 2024 (+28% vs 2021). Nurix Therapeutics, Inc. generated $-263M FCF in 2025 (-193% vs 2021).
FBIO vs NRIX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is FBIO or NRIX a better buy right now?
Analysts rate Fortress Biotech, Inc. (FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FBIO or NRIX?
Over the past 5 years, Nurix Therapeutics, Inc. (NRIX) delivered a total return of -55.9%, compared to -94.1% for Fortress Biotech, Inc. (FBIO). A $10,000 investment in NRIX five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NRIX returned -16.0% versus FBIO's -92.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FBIO or NRIX?
By beta (market sensitivity over 5 years), Fortress Biotech, Inc. (FBIO) is the lower-risk stock at 0.65β versus Nurix Therapeutics, Inc.'s 1.19β — meaning NRIX is approximately 84% more volatile than FBIO relative to the S&P 500.
04Which has better profit margins — FBIO or NRIX?
Fortress Biotech, Inc. (FBIO) is the more profitable company, earning -79.8% net margin versus -314.9% for Nurix Therapeutics, Inc. — meaning it keeps -79.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBIO leads at -191.4% versus -340.2% for NRIX. At the gross margin level — before operating expenses — NRIX leads at 77.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — FBIO or NRIX?
In this comparison, FBIO (1.0% yield) pays a dividend. NRIX does not pay a meaningful dividend and should not be held primarily for income.
06Is FBIO or NRIX better for a retirement portfolio?
For long-horizon retirement investors, Fortress Biotech, Inc. (FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 1.0% yield). Both have compounded well over 10 years (FBIO: -92.0%, NRIX: -16.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between FBIO and NRIX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. FBIO pays a dividend while NRIX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.